VIGL
NASDAQVigil Neuroscience Inc.
Price$8.06+5.86 (+265.76%)
2025-04-302025-08-04
Latest news
25 items- SECSEC Form 15-12G filed by Vigil Neuroscience Inc.15-12G - Vigil Neuroscience, Inc. (0001827087) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.SCHEDULE 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.SCHEDULE 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)
- SECSEC Form EFFECT filed by Vigil Neuroscience Inc.EFFECT - Vigil Neuroscience, Inc. (0001827087) (Filer)
- SECSEC Form EFFECT filed by Vigil Neuroscience Inc.EFFECT - Vigil Neuroscience, Inc. (0001827087) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vigil Neuroscience Inc.SCHEDULE 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)
- INSIDERLarge owner Atlas Venture Fund Xii, L.P. returned 5,836,874 shares to the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- SECSEC Form S-8 POS filed by Vigil Neuroscience Inc.S-8 POS - Vigil Neuroscience, Inc. (0001827087) (Filer)
- SECSEC Form S-8 POS filed by Vigil Neuroscience Inc.S-8 POS - Vigil Neuroscience, Inc. (0001827087) (Filer)
- SECSEC Form S-8 POS filed by Vigil Neuroscience Inc.S-8 POS - Vigil Neuroscience, Inc. (0001827087) (Filer)
- SECSEC Form S-8 POS filed by Vigil Neuroscience Inc.S-8 POS - Vigil Neuroscience, Inc. (0001827087) (Filer)
- SECSEC Form POS AM filed by Vigil Neuroscience Inc.POS AM - Vigil Neuroscience, Inc. (0001827087) (Filer)
- SECSEC Form POS AM filed by Vigil Neuroscience Inc.POS AM - Vigil Neuroscience, Inc. (0001827087) (Filer)
- INSIDERDirector Thistle Mary returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Kaufmann Petra4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERDirector Budd Haeberlein Samantha L. returned 17,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERChief Financial Officer Ziolkowski Jennifer Lynn returned 4,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERDirector Booth Bruce returned 5,841,874 shares to the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERDirector Vitorovic Stefan returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERPresident and CEO Magovcevic-Liebisch Ivana returned 222,687 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERSEC Form 4 filed by Chief Science Officer Gray David L. F.4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERDirector Bruhn Suzanne Louise returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERDirector Blanchard Cheryl R returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- INSIDERDirector Koenig Gerhard returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- SECSEC Form 25-NSE filed by Vigil Neuroscience Inc.25-NSE - Vigil Neuroscience, Inc. (0001827087) (Subject)
VIGL FAQ
7 questionsWhat does Vigil Neuroscience Inc. do?
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also...Where does VIGL stock trade?
Vigil Neuroscience Inc. (VIGL) is listed on NASDAQ.What sector and industry is VIGL in?
Vigil Neuroscience Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Vigil Neuroscience Inc. go public?
Vigil Neuroscience Inc. (VIGL) completed its IPO in 2022.What are analysts saying about VIGL?
Vigil Neuroscience Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Hold with a $800.00 price target on 2025-05-28.What companies are similar to VIGL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare VIGL side-by-side with any of them on Quantisnow.How can I track VIGL on Quantisnow?
Quantisnow aggregates Vigil Neuroscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VIGL to receive live email and push alerts on every new disclosure.